Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Evaluating the association of multiple single nucleotide polymorphisms with response to gemcitabine and platinum combination chemotherapy in urothelial carcinoma of the bladder
.

Alanee SR, Shah S, Zabor EC, Vijai J, Ostrovnaya I, Garcia-Grossman IR, Pendse DV, Littman J, Regazzi AM, Offit K, Bajorin DF.

Int J Clin Pharmacol Ther. 2017 Mar;55(3):203-209. doi: 10.5414/CP202856.

PMID:
28177276
2.

Outcome and Impact Evaluation of a Transgender Health Course for Health Profession Students.

Braun HM, Garcia-Grossman IR, Quiñones-Rivera A, Deutsch MB.

LGBT Health. 2017 Feb;4(1):55-61. doi: 10.1089/lgbt.2016.0119. Epub 2017 Jan 11.

PMID:
28075699
3.

Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer.

O'Donnell PH, Alanee S, Stratton KL, Garcia-Grossman IR, Cao H, Ostrovnaya I, Plimack ER, Manschreck C, Ganshert C, Smith ND, Steinberg GD, Vijai J, Offit K, Stadler WM, Bajorin DF.

Clin Genitourin Cancer. 2016 Dec;14(6):511-517. doi: 10.1016/j.clgc.2016.03.006. Epub 2016 Mar 10.

4.

The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.

Bambury RM, Benjamin DJ, Chaim JL, Zabor EC, Sullivan J, Garcia-Grossman IR, Regazzi AM, Ostrovnaya I, Apollo A, Xiao H, Voss MH, Iyer G, Bajorin DF, Rosenberg JE.

Oncologist. 2015 May;20(5):508-15. doi: 10.1634/theoncologist.2014-0354. Epub 2015 Apr 6.

5.

Comprehensive molecular characterization of urothelial bladder carcinoma.

Cancer Genome Atlas Research Network.

Nature. 2014 Mar 20;507(7492):315-22. doi: 10.1038/nature12965. Epub 2014 Jan 29.

6.

Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.

Iyer G, Al-Ahmadie H, Schultz N, Hanrahan AJ, Ostrovnaya I, Balar AV, Kim PH, Lin O, Weinhold N, Sander C, Zabor EC, Janakiraman M, Garcia-Grossman IR, Heguy A, Viale A, Bochner BH, Reuter VE, Bajorin DF, Milowsky MI, Taylor BS, Solit DB.

J Clin Oncol. 2013 Sep 1;31(25):3133-40. doi: 10.1200/JCO.2012.46.5740. Epub 2013 Jul 29.

7.

Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host.

Gallagher DJ, Vijai J, Hamilton RJ, Ostrovnaya I, Iyer G, Garcia-Grossman IR, Kim PH, Przybylo JA, Alanee S, Riches JC, Regazzi AM, Milowsky MI, Offit K, Bajorin DF.

Ann Oncol. 2013 Sep;24(9):2414-21. doi: 10.1093/annonc/mdt225. Epub 2013 Jul 29.

PMID:
23897706
8.

Phase II study of everolimus in metastatic urothelial cancer.

Milowsky MI, Iyer G, Regazzi AM, Al-Ahmadie H, Gerst SR, Ostrovnaya I, Gellert LL, Kaplan R, Garcia-Grossman IR, Pendse D, Balar AV, Flaherty AM, Trout A, Solit DB, Bajorin DF.

BJU Int. 2013 Aug;112(4):462-70. doi: 10.1111/j.1464-410X.2012.11720.x. Epub 2013 Apr 3.

9.

Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.

Balar AV, Apolo AB, Ostrovnaya I, Mironov S, Iasonos A, Trout A, Regazzi AM, Garcia-Grossman IR, Gallagher DJ, Milowsky MI, Bajorin DF.

J Clin Oncol. 2013 Feb 20;31(6):724-30. doi: 10.1200/JCO.2012.42.5215. Epub 2013 Jan 22.

Supplemental Content

Loading ...
Support Center